No comment here be it rosey, objective or negative makes any difference in pps or volume. Per 2nd quarter report, RDGL has ~10 months of cash on hand. Unless RDGL becomes profitable via IsoPet sales within that timeframe, which looks very unlikely, this remains solely an FDA play, and only IDE approval can turn the page here. That's a reasonable risk/reward/time balance for me, but may not be for everyone.